AGEN 1423
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 3, 2019 (NCT03954704)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-1ANTAGONIST
TGFB1 antagonist
- 5'-nucleotidaseANTAGONIST
NT5E antagonist
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06300463 | Phase 2 | Mar 26, 2024 | Agenus Inc., Cornell University |
| NCT05632328 | Phase 2 | Apr 30, 2023 | Agenus Inc., Harvard University |
| NCT03954704 | Phase 1 | Jun 3, 2019 | Gilead Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agenus Inc. | For profit | 2 | 0 | 1 | 2023 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Gilead Sciences | For profit | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1